LONDON, UNITED KINGDOM--(Marketwired - Apr 28, 2017) -  Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Plandaí. 

Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past 18 years. He was he was with NutraGenesis for 3.5 years, and has recently, before Plandaí, been working as an independent sales representative for numerous worldwide companies. Since 2016, Mr. Jones has overseen all North American sales efforts for Plandaí. As the new head of sales and marketing, his responsibilities will expand to overseeing all global sales efforts, working with the company's independent sales reps and distributors, building additional sales channels, and growing the Phytofare® brand.

Callum Cottrell-Duffield, President of Plandaí, commented, "Having worked with Ezra for the past year, I have been impressed with his passion for the product and knowledge of the industry. He has been instrumental in opening our largest accounts and is a driven salesman. As we now expand into a global brand and introduce new products in the coming year, Ezra's experience in building and training a sales force will be invaluable."

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing green tea on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information:

Plandai Biotechnology, Inc.
Hannah Merrill